Additional Information
Book Details
Abstract
Ferri’s Clinical Advisor 2018 is the most efficient, intuitive, and thorough resource of its kind, trusted by physicians to provide current diagnosis and treatment recommendations for hundreds of common medical conditions. The renowned "5 books in 1" format organizes vast amounts of data in a user-friendly, accessible manner, allowing quick retrieval of essential information. You’ll find guidance on diseases and disorders, differential diagnoses, and laboratory tests– updated annually by experts in key clinical fields. Medical algorithms and clinical practice guidelines round out the core content.
- Updated content by experts in key clinical fields helps you keep pace with the speed of modern medicine.
- Popular "5 books in 1" format includes cross-references, outlines, bullets, tables, boxes, and algorithms to help expedite search.
- Features 30 all-new topics, including Zika virus, hepatitis E, asthma-COPD overlap syndrome, drug-induced parenchymal lung disease, binge eating disorder, hereditary breast and ovarian cancer syndrome, transient global amnesia, and more.
- Updates 900 topics with the latest developments in medicine over the past year.
- Contains significantly expanded coverage throughout, including nearly 200 new illustrations, more than 100 new tables and boxes, 50 new differential diagnoses, and 30 new algorithms.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| CLINICAL DISORDERS | ES1 | ||
| CARDIOVASCULAR DISEASES | ES1 | ||
| DERMATOLOGY | ES1 | ||
| ENDOCRINOLOGY | ES1 | ||
| ENVIRONMENTAL MEDICINE | ES1 | ||
| GASTROENTEROLOGY | ES1 | ||
| GYNECOLOGY AND OBSTETRICS | ES2 | ||
| HEMATOLOGY/ONCOLOGY | ES2 | ||
| INFECTIOUS DISEASES | ES3 | ||
| MISCELLANEOUS | ES3 | ||
| Ferri’s Clinical Advisor, 2018: 5 Books in 1 | i | ||
| Copyright | ii | ||
| Section Editors | iii | ||
| Contributors | v | ||
| Dedication | xxxi | ||
| Preface | xxxii | ||
| EVALUATION OF EVIDENCE | xxxiii | ||
| SOURCES OF EVIDENCE | xxxiii | ||
| Ferri’s Clinical Advisor 2018 — How to Use This Book | xxxiv | ||
| Contents | xxxv | ||
| Detailed Contents | xxxvi | ||
| I - Diseases and Disorders | 1 | ||
| A | 3 | ||
| ?Abdominal Aortic Aneurysm | 3 | ||
| ?Basic Information | 3 | ||
| DEFINITION | 3 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 3 | ||
| ETIOLOGY | 3 | ||
| NATURAL HISTORY | 3 | ||
| SCREENING AND MONITORING | 3 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 3 | ||
| ?Diagnosis | 3 | ||
| DIFFERENTIAL DIAGNOSIS | 3 | ||
| LABORATORY TESTS | 4 | ||
| IMAGING STUDIES | 4 | ||
| ?Treatment | 5 | ||
| NONPHARMACOLOGIC THERAPY | 5 | ||
| ACUTE GENERAL RX | 5 | ||
| CHRONIC RX | 5 | ||
| ?Pearls & Considerations | 6 | ||
| COMMENTS | 6 | ||
| SUGGESTED READINGS | 6 | ||
| RELATED CONTENT | 6 | ||
| Abdominal Compartment Syndrome | 7 | ||
| ?Basic Information | 7 | ||
| DEFINITION | 7 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 7 | ||
| Incidence: Very few studies have examined the incidence of ACS outside of trauma patients, among whom it ranges from 1% to 14%, ... | 7 | ||
| Risk Factors: The biggest risk factor for developing ACS is critical illness stemming from a wide array of medical and surgical ... | 7 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 7 | ||
| ETIOLOGY | 7 | ||
| ?Diagnosis | 7 | ||
| DIFFERENTIAL DIAGNOSIS | 7 | ||
| WORKUP | 7 | ||
| LABORATORY TEST(S) | 7 | ||
| IMAGING STUDIES | 7 | ||
| ?Treatment | 7 | ||
| NONPHARMACOLOGIC THERAPY | 7 | ||
| ACUTE GENERAL RX | 8 | ||
| DISPOSITION | 8 | ||
| REFERRAL | 8 | ||
| ?Pearls & Considerations | 8 | ||
| COMMENTS | 8 | ||
| SUGGESTED READINGS | 8 | ||
| Abruptio Placentae | 9 | ||
| ?Basic Information | 9 | ||
| DEFINITION | 9 | ||
| SYNONYM | 9 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 9 | ||
| Incidence (In U.S.): One in 86 to 206 births; 80% occur before the onset of labor | 9 | ||
| Risk Factors: Hypertension (greatest association), trauma, polyhydramnios, multifetal gestation, smoking, use of cocaine, chorio... | 9 | ||
| Recurrence Rate: 5% to 17%, some studies showing a 5- to 10-fold increase in risk; with two prior episodes, 25% | 9 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 9 | ||
| ETIOLOGY | 9 | ||
| ?Diagnosis | 9 | ||
| DIFFERENTIAL DIAGNOSIS | 9 | ||
| WORKUP | 9 | ||
| LABORATORY TESTS | 9 | ||
| IMAGING STUDIES | 9 | ||
| ?Treatment | 10 | ||
| ACUTE GENERAL RX | 10 | ||
| CHRONIC RX | 10 | ||
| DISPOSITION | 10 | ||
| REFERRAL | 10 | ||
| RELATED CONTENT | 10 | ||
| Acetaminophen Poisoning | 11 | ||
| ?Basic Information | 11 | ||
| DEFINITION | 11 | ||
| SYNONYMS | 11 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 11 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 11 | ||
| ETIOLOGY | 11 | ||
| ?Diagnosis | 11 | ||
| DIFFERENTIAL DIAGNOSIS | 11 | ||
| WORKUP | 11 | ||
| LABORATORY TESTS | 11 | ||
| ?Treatment | 11 | ||
| NONPHARMACOLOGIC THERAPY | 11 | ||
| ACUTE GENERAL RX | 11 | ||
| DISPOSITION | 11 | ||
| REFERRAL | 11 | ||
| RELATED CONTENT | 11 | ||
| Achalasia | 12 | ||
| ?Basic Information | 12 | ||
| DEFINITION | 12 | ||
| SYNONYMS | 12 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 12 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 12 | ||
| ETIOLOGY | 12 | ||
| ?Diagnosis | 12 | ||
| DIFFERENTIAL DIAGNOSIS | 12 | ||
| WORKUP | 12 | ||
| LABORATORY TESTS | 12 | ||
| IMAGING STUDIES | 12 | ||
| ?Treatment | 13 | ||
| NONPHARMACOLOGIC THERAPY | 13 | ||
| GENERAL RX | 13 | ||
| ?Pearls & Considerations | 13 | ||
| COMMENTS | 13 | ||
| Anchor 207 | 13 | ||
| SUGGESTED READINGS | 13 | ||
| RELATED CONTENT | 13 | ||
| SUGGESTED READINGS | 13.e1 | ||
| Achilles Tendon Rupture | 13.e2 | ||
| ?Basic Information | 13.e2 | ||
| DEFINITION | 13.e2 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 13.e2 | ||
| Incidence: In the general population, Achilles tendon ruptures occur in 7 per 100,000 individuals. Recreational activities are t... | 13.e2 | ||
| Peak Incidence: 30- to 40-year age group | 13.e2 | ||
| Predominant Age: 30- to 55-year age group | 13.e2 | ||
| Risk Factors: General risk factors include recreational athletes, stop-and-go sports (e.g., basketball, tennis, and soccer), pre... | 13.e2 | ||
| CLINICAL PRESENTATION | 13.e2 | ||
| PHYSICAL FINDINGS | 13.e2 | ||
| ETIOLOGY/MECHANISM OF INJURY | 13.e2 | ||
| ?Diagnosis | 13.e2 | ||
| DIFFERENTIAL DIAGNOSIS | 13.e2 | ||
| WORKUP | 13.e2 | ||
| IMAGING STUDIES | 13.e2 | ||
| ?Treatment | 13.e2 | ||
| SURGICAL TREATMENT | 13.e3 | ||
| REFERRAL | 13.e3 | ||
| ?Pearls & Considerations | 13.e3 | ||
| PREVENTION | 13.e3 | ||
| SUGGESTED READINGS | 13.e3 | ||
| RELATED CONTENT | 13.e3 | ||
| Acne Vulgaris | 14 | ||
| ?Basic Information | 14 | ||
| DEFINITION | 14 | ||
| SYNONYMS | 14 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 14 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 14 | ||
| ETIOLOGY | 14 | ||
| ?Diagnosis | 14 | ||
| DIFFERENTIAL DIAGNOSIS | 14 | ||
| WORKUP | 14 | ||
| LABORATORY TESTS | 14 | ||
| ?Treatment | 14 | ||
| NONPHARMACOLOGIC THERAPY | 14 | ||
| ACUTE GENERAL RX | 15 | ||
| REFERRAL | 15 | ||
| ?Pearls & Considerations | 15 | ||
| COMMENTS | 15 | ||
| SUGGESTED READINGS | 15 | ||
| RELATED CONTENT | 15 | ||
| Acoustic Neuroma | 16 | ||
| ?Basic Information | 16 | ||
| DEFINITION | 16 | ||
| SYNONYMS | 16 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 16 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 16 | ||
| ETIOLOGY | 16 | ||
| ?Diagnosis | 16 | ||
| DIFFERENTIAL DIAGNOSIS | 16 | ||
| WORKUP | 16 | ||
| LABORATORY TESTS | 16 | ||
| IMAGING STUDIES | 16 | ||
| ?Treatment | 16 | ||
| NONPHARMACOLOGIC THERAPY | 16 | ||
| GENERAL RX | 16 | ||
| DISPOSITION | 16 | ||
| REFERRAL | 16 | ||
| ?Pearls & Considerations | 16 | ||
| COMMENTS | 16 | ||
| PATIENT/FAMILY EDUCATION | 16 | ||
| SUGGESTED READINGS | 16 | ||
| RELATED CONTENT | 16 | ||
| SUGGESTED READINGS | 16.e1 | ||
| Acquired Immunodeficiency Syndrome | 17 | ||
| ?BASIC INFORMATION | 17 | ||
| DEFINITION | 17 | ||
| SYNONYMS | 17 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 17 | ||
| Incidence (In U.S.) | 17 | ||
| Prevalence (In U.S.) | 17 | ||
| Predominant Sex: Men constitute approximately 75% of incident AIDS diagnoses in the U.S.; more than 55% of AIDS diagnoses occur ... | 17 | ||
| Predominant Age: The predominant age group diagnosed with AIDS is 40-49 years of age, closely followed by 30-39 years of age | 17 | ||
| Peak Incidence: Ages 45-49 | 17 | ||
| Genetics | 17 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 17 | ||
| ETIOLOGY | 17 | ||
| ?DIAGNOSIS | 17 | ||
| DIFFERENTIAL DIAGNOSIS | 17 | ||
| WORKUP | 17 | ||
| LABORATORY TESTS | 17 | ||
| IMAGING STUDIES | 17 | ||
| ?TREATMENT | 17 | ||
| NONPHARMACOLOGIC THERAPY | 17 | ||
| ACUTE GENERAL RX | 18 | ||
| CHRONIC RX | 18 | ||
| DISPOSITION | 18 | ||
| REFERRAL | 24 | ||
| SUGGESTED READINGS | 24 | ||
| RELATED CONTENT | 24 | ||
| Acromegaly | 24.e8 | ||
| ?Basic Information | 24.e8 | ||
| DEFINITION | 24.e8 | ||
| SYNONYMS | 24.e8 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 24.e8 | ||
| Incidence: 3 to 4 new cases per 1 million persons annually | 24.e8 | ||
| Prevalence: 50 to 60 cases per 1 million persons, with some estimates as high as 90 cases per 1 million persons | 24.e8 | ||
| Predominant Sex: No sexual predominance | 24.e8 | ||
| Mean Age at Diagnosis: Men: 40 yr; women: 45 yr | 24.e8 | ||
| Risk Factors | 24.e8 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 24.e8 | ||
| ETIOLOGY | 24.e8 | ||
| ?Diagnosis | 24.e8 | ||
| DIFFERENTIAL DIAGNOSIS | 24.e8 | ||
| WORKUP | 24.e8 | ||
| LABORATORY TESTS | 24.e8 | ||
| IMAGING STUDIES | 24.e8 | ||
| ?Treatment | 24.e8 | ||
| SURGERY | 24.e8 | ||
| RADIOTHERAPY | 24.e8 | ||
| MEDICAL THERAPY | 24.e8 | ||
| CHRONIC RX | 24.e8 | ||
| DISPOSITION | 24.e9 | ||
| SUGGESTED READINGS | 24.e9 | ||
| RELATED CONTENT | 24.e9 | ||
| Actinic Keratosis | 25 | ||
| ?Basic Information | 25 | ||
| DEFINITION | 25 | ||
| SYNONYMS | 25 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 25 | ||
| Incidence: In regions of the northern hemisphere, 11%-25% of adults have a minimum of one AK. In regions closer to the equator, ... | 25 | ||
| Peak Incidence: The risk of squamous cell carcinoma in patients with AK is 6%-10%. Risk factors associated with increased risk o... | 25 | ||
| Prevalence | 25 | ||
| Predominant Sex and Age: Males > females, age 65-74. Occurs most in those with fair complexions who burn rather than tan followi... | 25 | ||
| Genetics: There is increased frequency of non-melanoma skin cancers connected to squamous cell cancers with the genetic conditio... | 25 | ||
| Risk Factors | 25 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 25 | ||
| ETIOLOGY | 25 | ||
| ?Diagnosis | 25 | ||
| DIFFERENTIAL DIAGNOSIS | 25 | ||
| WORKUP | 25 | ||
| LABORATORY TESTS | 25 | ||
| ?Treatment | 26 | ||
| NONPHARMACOLOGIC THERAPY | 26 | ||
| ACUTE GENERAL RX | 26 | ||
| REFERRAL | 26 | ||
| ?Pearls & Considerations | 26 | ||
| COMMENTS | 26 | ||
| PREVENTION | 26 | ||
| SUGGESTED READINGS | 26 | ||
| SUGGESTED READINGS | 26.e1 | ||
| Actinomycosis | 26.e2 | ||
| ?BASIC INFORMATION | 26.e2 | ||
| DEFINITION | 26.e2 | ||
| SYNONYMS | 26.e2 | ||
| EPIDEMIOLOGY & DEMOGRAPHICS | 26.e2 | ||
| Geographic Distribution | 26.e2 | ||
| Incidence | 26.e2 | ||
| PHYSICAL FINDINGS & CLINICAL PRESENTATION | 26.e2 | ||
| ETIOLOGY | 26.e2 | ||
| ?DIAGNOSIS | 26.e3 | ||
| DIFFERENTIAL DIAGNOSIS | 26.e3 | ||
| WORKUP | 26.e3 | ||
| LABORATORY TESTS | 26.e3 | ||
| IMAGING STUDIES | 26.e3 | ||
| ?TREATMENT | 26.e3 | ||
| NONPHARMACOLOGIC THERAPY | 26.e3 | ||
| ACUTE GENERAL RX | 26.e3 | ||
| CHRONIC RX | 26.e3 | ||
| DISPOSITION | 26.e3 | ||
| REFERRAL | 26.e3 | ||
| ?PEARLS & CONSIDERATIONS | 26.e3 | ||
| COMMENTS | 26.e3 | ||
| II - Differential Diagnosis | 1385 | ||
| A | 1387 | ||
| ABDOMINAL DISTENTION | 1387 | ||
| NONMECHANICAL OBSTRUCTION | 1387 | ||
| MECHANICAL OBSTRUCTION | 1387 | ||
| ABDOMINAL PAIN, ADOLESCENCE50 | 1387 | ||
| ABDOMINAL PAIN, CHILDHOOD50 | 1387 | ||
| ABDOMINAL PAIN, CHRONIC LOWER72 | 1387 | ||
| ORGANIC DISORDERS | 1387 | ||
| III - Clinical Algorithms | 1547 | ||
| Additional algorithms available at www.expertconsult.com | 1549 | ||
| A\r | 1550 | ||
| Abdominal Abscess | 1550 | ||
| Abdominal Pain, Acute | 1551 | ||
| ABDOMINAL PAIN, RIGHT UPPER QUADRANT | 1552 | ||
| Acid-Base Homeostasis | 1553 | ||
| Acid-Base Homeostatasis—cont’d | 1554 | ||
| Acidosis, Meta bolic | 1555 | ||
| Acidosis, Respiratratory, Acute | 1556 | ||
| Acidosis, Respirat ory, Chronic | 1557 | ||
| ADRENAL INCIDENTALOMA | 1557.e1 | ||
| Adrenal Mass | 1558 | ||
| Airway Obstruction, Malignant | 1559 | ||
| Alcohol Poisoning | 1560 | ||
| Allergic Reaction to Vaccines | 1561 | ||
| Alkalosis, metabolic | 1562 | ||
| ALKALOSIS, RESPIRATORY TREATMENT | 1563 | ||
| ALTERED MENTAL STATUS AND COMA | 1564 | ||
| Alveolar Hemorrhage | 1565 | ||
| Alveolar Hemorrhage—cont’d | 1566 | ||
| Ambiguous Genitalia | 1567 | ||
| Anemia | 1568 | ||
| Anemia in Newborn | 1568.e1 | ||
| ANEMIA, MACROCYTIC | 1569 | ||
| ANEMIA, MICROCYTIC | 1569 | ||
| ANEMIA WITH RETICULOCYTOSIS | 1570.e1 | ||
| Anisocoria | 1571 | ||
| Anisocoria—cont’d | 1572 | ||
| Anorecta l Complaints | 1573 | ||
| Anorexia | 1574 | ||
| Anticholinergic Poisoning | 1575 | ||
| ARTHRALGIA LIMITED TO ONEOR FEW JOINT | 1576 | ||
| ASPIRATION, GASTRIC CONTENTS | 1576.e1 | ||
| ASPIRATION, ORAL CONTENTS | 1576.e2 | ||
| Ataxia, Progressive | 1577 | ||
| Azoospermia | 1578 | ||
| B | 1579 | ||
| Back Pain | 1579 | ||
| Bleeding and Bruising Problems | 1579.e1 | ||
| Bleeding Disorder, Congenitatal | 1579.e2 | ||
| Bleeding Disorders | 1580 | ||
| Bleeding, Early Pregnancy | 1580.e1 | ||
| Bleeding, Gastrointestinal | 1581 | ||
| BLEEDING,GASTROINTESTINAL—cont’d | 1582 | ||
| Bleeding, Neonate | 1582.e1 | ||
| Bleeding, Vaginal | 1583 | ||
| Bleeding, Vaginal—cont’d | 1583 | ||
| Bleeding, Variceal | 1584.e1 | ||
| Bradycardia | 1585 | ||
| BRADYCDYCARDIA, PEDIATRIC PATIENT | 1585 | ||
| IV - Laboratory Tests and Interpretation of Results | 1769 | ||
| INTRODUCTION | 1770 | ||
| A | 1771 | ||
| ACE LEVEL | 1771 | ||
| ACETONE (SERUM OR PLASMA) | 1771 | ||
| ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY | 1771 | ||
| ACID-BASE REFERENCE VALUES | 1771 | ||
| ACID PHOSPHATASE (SERUM) | 1771 | ||
| ACID SERUM TEST | 1771 | ||
| ACTIVATED CLOTTING TIME (ACT) | 1771 | ||
| ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT, APTT) | 1771 | ||
| ADRENOCORTICOTROPIC HORMONE | 1771 | ||
| ALANINE AMINOPEPTIDASE | 1771 | ||
| Normal | 1771 | ||
| ALANINE AMINOTRANSFERASE (ALT, SGPT) | 1771 | ||
| ALBUMIN (SERUM) | 1773 | ||
| ALCOHOL DEHYDROGENASE | 1773 | ||
| ALDOLASE (SERUM) | 1773 | ||
| ALDOSTERONE | 1773 | ||
| ALKALINE PHOSPHATASE (ALP) (SERUM) | 1774 | ||
| ALPHA-1-ANTITRYPSIN (SERUM) | 1774 | ||
| ALPHA-1-FETOPROTEIN (SERUM) | 1774 | ||
| ALT | 1774 | ||
| ALUMINUM (SERUM) | 1774 | ||
| AMA | 1774 | ||
| AMEBIASIS SEROLOGIC TEST | 1774 | ||
| AMINOLEVULINIC ACID (Δ-ALA) (24-HR URINE COLLECTION) | 1774 | ||
| AMMONIA (SERUM) | 1774 | ||
| AMYLASE (SERUM) | 1774 | ||
| AMYLASE, URINE | 1774 | ||
| AMYLOID A PROTEIN (SERUM) | 1774 | ||
| ANA | 1774 | ||
| ANCA | 1774 | ||
| ANDROSTENEDIONE (SERUM) | 1774 | ||
| Normal | 1774 | ||
| ANGIOTENSIN II | 1775 | ||
| ANGIOTENSIN-CONVERTING ENZYME (ACE LEVEL) | 1775 | ||
| ANH | 1775 | ||
| ANION GAP | 1775 | ||
| ANTICARDIOLIPIN ANTIBODY (ACA) | 1775 | ||
| ANTICOAGULANT | 1775 | ||
| ANTIDIURETIC HORMONE | 1775 | ||
| ANTI-DNA | 1776 | ||
| ANTI-DS DNA | 1776 | ||
| ANTIGLOBULIN TEST | 1776 | ||
| ANTIGLOMERULAR BASEMENT ANTIBODY | 1776 | ||
| ANTIHISTONE | 1776 | ||
| ANTIMITOCHONDRIAL ANTIBODY (AMA, MITOCHONDRIAL ANTIBODY) | 1776 | ||
| ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) | 1776 | ||
| ANTINUCLEAR ANTIBODY (ANA) | 1776 | ||
| ANTI-RNP ANTIBODY | 1777 | ||
| ANTI-SCL-70 | 1777 | ||
| ANTI-SM (ANTI-SMITH) ANTIBODY | 1777 | ||
| ANTI-SMOOTH MUSCLE ANTIBODY | 1777 | ||
| ANTISTREPTOLYSIN O TITER (STREPTOZYME, ASLO TITER) | 1777 | ||
| ANTITHROMBIN III | 1777 | ||
| APOLIPOPROTEIN A-1 (APO A-1) | 1777 | ||
| APOLIPOPROTEIN B (APO B) | 1777 | ||
| ARTERIAL BLOOD GASES | 1777 | ||
| ARTHROCENTESIS FLUID | 1778 | ||
| ASLO TITER | 1778 | ||
| ASPARTATE AMINOTRANSFERASE (AST, SGOT) | 1778 | ||
| ATRIAL NATRIURETIC HORMONE (ANH) | 1778 | ||
| B | 1779 | ||
| B-Type Natriuretic Peptide (BNP) | 1779 | ||
| BASOPHIL COUNT | 1779 | ||
| BICARBONATE | 1779 | ||
| BILE, URINE | 1779 | ||
| BILIRUBIN, DIRECT (CONJUGATED BILIRUBIN) | 1779 | ||
| BILIRUBIN, INDIRECT (UNCONJUGATED BILIRUBIN) | 1779 | ||
| BILIRUBIN, TOTAL | 1779 | ||
| BILIRUBIN, URINE | 1779 | ||
| BLADDER TUMOR ASSOCIATED ANTIGEN | 1779 | ||
| BLEEDING TIME (MODIFIED IVY METHOD) | 1779 | ||
| BLOOD VOLUME, TOTAL | 1781 | ||
| BNP | 1781 | ||
| BORDETELLA PERTUSSIS SEROLOGY | 1781 | ||
| BRCA ANALYSIS | 1781 | ||
| DESCRIPTION OF ANALYSIS | 1781 | ||
| Comprehensive BRCA analysis | 1781 | ||
| Interpretive Criteria | 1781 | ||
| BREATH HYDROGEN TEST (HYDROGEN BREATH TEST) | 1781 | ||
| BUN | 1781 | ||
| C | 1781 | ||
| C282Y and H63D Mutation Analysis | 1781 | ||
| C3 | 1781 | ||
| C4 | 1781 | ||
| CALCITONIN (SERUM) | 1781 | ||
| CALCIUM (SERUM) | 1782 | ||
| ELEVATED | 1782 | ||
| CALCIUM, URINE | 1782 | ||
| CANCER ANTIGEN 15-3 (CA 15-3) | 1782 | ||
| CANCER ANTIGEN 27-29 (CA 27-29) | 1784 | ||
| CANCER ANTIGEN 72-4 (CA 72-4) | 1784 | ||
| CANCER ANTIGEN 125 (CA 125) | 1784 | ||
| MALIGNANT | 1784 | ||
| BENIGN | 1784 | ||
| CAPTOPRIL STIMULATION TEST | 1784 | ||
| CARBAMAZEPINE (TEGRETOL) | 1784 | ||
| CARBOHYDRATE ANTIGEN 19-9 | 1784 | ||
| CARBON DIOXIDE, PARTIAL PRESSURE | 1784 | ||
| Normal | 1784 | ||
| CARBON MONOXIDE | 1784 | ||
| CARBOXYHEMOGLOBIN | 1784 | ||
| CARCINOEMBRYONIC ANTIGEN (CEA) | 1784 | ||
| Normal range | 1784 | ||
| Elevated in | 1784 | ||
| CAROTENE (SERUM) | 1784 | ||
| CATECHOLAMINES, URINE | 1784 | ||
| CBC | 1784 | ||
| CD40 LIGAND | 1784 | ||
| CD4+ T-LYMPHOCYTE COUNT (CD4+ T-CELLS) | 1784 | ||
| CEA | 1784 | ||
| CEREBROSPINAL FLUID (CSF) | 1784 | ||
| CERULOPLASMIN (SERUM) | 1785 | ||
| CHLAMYDIA GROUP ANTIBODY SEROLOGIC TEST | 1785 | ||
| CHLAMYDIA TRACHOMATIS PCR | 1785 | ||
| CHLORIDE (SERUM) | 1785 | ||
| CHLORIDE (SWEAT) | 1785 | ||
| CHLORIDE, URINE | 1785 | ||
| CHOLECYSTOKININ-PANCREOZYMIN (CCK, CCK-PZ) | 1785 | ||
| CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN | 1785 | ||
| CHOLESTEROL, LOW-DENSITY LIPOPROTEIN | 1785 | ||
| CHOLESTEROL, TOTAL | 1785 | ||
| CHORIONIC GONADOTROPINS, HUMAN (SERUM) (HCG) | 1785 | ||
| CHYMOTRYPSIN | 1788 | ||
| CIRCULATING ANTICOAGULANT (LUPUS ANTICOAGULANT) | 1788 | ||
| CK | 1789 | ||
| CLONIDINE SUPPRESSION TEST | 1789 | ||
| CLOSTRIDIUM DIFFICILE TOXIN ASSAY (STOOL) | 1789 | ||
| CO | 1789 | ||
| COAGULATION FACTORS | 1789 | ||
| COBALAMIN, SERUM | 1789 | ||
| COLD AGGLUTININS TITER | 1789 | ||
| COMPLEMENT | 1790 | ||
| COMPLEMENT DEFICIENCY | 1790 | ||
| COMPLETE BLOOD COUNT (CBC) | 1790 | ||
| CONJUGATED BILIRUBIN | 1792 | ||
| COPPER (SERUM) | 1792 | ||
| COPPER, URINE | 1792 | ||
| CORTICOTROPIN RELEASING HORMONE (CRH) STIMULATION TEST | 1792 | ||
| CORTISOL, PLASMA | 1793 | ||
| Normal range | 1793 | ||
| C-PEPTIDE | 1793 | ||
| COOMBS DIRECT | 1793 | ||
| COOMBS INDIRECT | 1793 | ||
| CPK | 1793 | ||
| C-REACTIVE PROTEIN | 1793 | ||
| C-REACTIVE PROTEIN, HIGH SENSITIVITY (HS-CRP, CARDIO-CRP) | 1793 | ||
| Interpretation of Results | 1793 | ||
| CREATINE KINASE (CK, CPK) | 1793 | ||
| CREATINE KINASE ISOENZYMES | 1794 | ||
| CK-BB | 1794 | ||
| CK-MB | 1794 | ||
| CK-MM | 1794 | ||
| CREATININE (SERUM) | 1794 | ||
| CREATININE CLEARANCE | 1795 | ||
| CREATININE, URINE | 1795 | ||
| CRYOGLOBULINS (SERUM) | 1795 | ||
| CRYPTOSPORIDIUM ANTIGEN BY EIA (STOOL) | 1795 | ||
| CSF | 1795 | ||
| CYSTATIN C | 1795 | ||
| CYSTIC FIBROSIS PCR | 1795 | ||
| CYTOMEGALOVIRUS BY PCR | 1795 | ||
| D | 1795 | ||
| d-Dimer | 1795 | ||
| Normal range | 1795 | ||
| V - Clinical Practice Guidelines | 1845 | ||
| PART A - THE PERIODIC HEALTH EXAMINATION | 1847 | ||
| PART B - IMMUNIZATIONS AND CHEMOPROPHYLAXIS | 1847 | ||
| Childhood and Adolescent Immunizations, 1859 | 1847 | ||
| General Recommendations on Immunization, 1865 | 1847 | ||
| Immunizations for Adults, 1876 | 1847 | ||
| Recommendations and Implementation Strategies for Hepatitis B Vaccination of Adults, 1889 | 1848 | ||
| Hepatitis A Prophylaxis, 1892 | 1848 | ||
| Influenza Treatment and Prophylaxis, 1893 | 1848 | ||
| HIV Testing and Postexposure Prophylaxis, 1897 | 1848 | ||
| Endocarditis Prophylaxis, 1905 | 1848 | ||
| Hepatitis C Testing, 1907 | 1848 | ||
| Hepatitis B Virus Postexposure Protection for Health Care Personnel, 1909 | 1848 | ||
| A • THE PERIODIC HEALTH EXAMINATION | 1849 | ||
| AGE-SPECIFIC CHARTS | 1849 | ||
| B • IMMUNIZATIONS AND CHEMOPROPHYLAXIS | 1859 | ||
| Childhood and Adolescent Immunizations | 1859 | ||
| General Recommendations on Immunization | 1865 | ||
| VACCINE ADMINISTRATION* | 1872 | ||
| INFECTION CONTROL AND STERILE TECHNIQUE | 1872 | ||
| INFANTS (AGED <12 MONTHS) | 1872 | ||
| Toddlers and Older Children (Aged 12 Months to 10 Years) | 1872 | ||
| Adolescents and Adults (Aged >11 Years) | 1872 | ||
| SUBCUTANEOUS INJECTIONS | 1872 | ||
| Immunizations for Adults | 1876 | ||
| HEPATITIS A PROPHYLAXIS | 1892 | ||
| Influenza Treatment and Prophylaxis | 1893 | ||
| INDICATIONS FOR USE OF ANTIVIRALS | 1895 | ||
| PERSONS FOR WHOM ANTIVIRAL TREATMENT SHOULD BE CONSIDERED | 1895 | ||
| PERSONS FOR WHOM ANTIVIRAL CHEMOPROPHYLAXIS SHOULD BE CONSIDERED DURING PERIODS OF INCREASED INFLUENZA ACTIVITY IN THE COMMUNITY... | 1895 | ||
| RECOMMENDATIONS FOR HIV TESTING OF ADULTS, ADOLESCENTS, AND PREGNANT WOMEN | 1897 | ||
| RECOMMENDATIONS FOR ADULTS AND ADOLESCENTS | 1897 | ||
| The CDC recommends that diagnostic human immunodeficiency virus (HIV) testing and opt-out HIV screening be a part of routine cli... | 1897 | ||
| SCREENING FOR HIV INFECTION | 1897 | ||
| REPEAT SCREENING | 1897 | ||
| CONSENT AND PRETEST INFORMATION | 1897 | ||
| DIAGNOSTIC TESTING FOR HIV INFECTION | 1897 | ||
| HIV SCREENING FOR PREGNANT WOMEN AND THEIR INFANTS* | 1897 | ||
| Universal Opt-Out Screening | 1897 | ||
| ADDRESSING REASONS FOR DECLINING TESTING | 1897 | ||
| Timing of HIV Testing | 1897 | ||
| Rapid Testing During Labor | 1898 | ||
| Postpartum/Newborn Testing | 1898 | ||
| Confirmatory Testing | 1898 | ||
| HEPATITIS C TESTING | 1907 | ||
| HEPATITIS B VIRUS POSTEXPOSURE PROTECTION FOR HEALTH CARE PERSONNEL | 1909 | ||
| APPENDIX | 1911 | ||
| Ia - Definitions of Complementary and Alternative Medicine Terms | 1913 | ||
| Ib - Relaxation Techniques | 1915 | ||
| Ic - Overview of Selected Natural Products | 1917 | ||
| Id - Natural Products and Drug Interactions | 1920 | ||
| Ie - Commonly Ingested Plants with Significant Toxic Potential | 1924 | ||
| If - Herbs Associated with Toxicity | 1925 | ||
| Ig - Websites Providing Data on Herbal Therapy Hazards | 1926 | ||
| IIa - Dietary Supplements: What Every Primary Care Provider Should Know | 1927 | ||
| IIb - Vitamins and Their Functions | 1929 | ||
| IIc - Nutritional Trace Elementsand Their Clinical Implications | 1934 | ||
| IId - Summary of Vitamin and Mineral Deficiencies | 1937 | ||
| IIIa - Historical and Physical Findingsin Poisoning | 1939 | ||
| IIIb - Recognizable Poison Syndromes | 1941 | ||
| IIIc - Antidotes and Indications for Use | 1942 | ||
| IV - Impairment and Disability Issues | 1947 | ||
| WORKERS’ COMPENSATION | 1947 | ||
| PERSONAL INJURY | 1948 | ||
| PRIVATE DISABILITY | 1948 | ||
| CONCLUSION | 1948 | ||
| SUGGESTED READINGS | 1948 | ||
| V - Primary Care Procedures1 | 1948.e1 | ||
| VI - Patient Teaching Guides | e1 | ||
| Index | 1949 | ||
| A | 1949 | ||
| B | 1955 | ||
| C | 1958 | ||
| D | 1965 | ||
| E | 1968 | ||
| F | 1971 | ||
| G | 1973 | ||
| H | 1974 | ||
| I | 1978 | ||
| J | 1981 | ||
| K | 1981 | ||
| L | 1981 | ||
| M | 1984 | ||
| N | 1987 | ||
| O | 1989 | ||
| P | 1990 | ||
| Q | 1997 | ||
| R | 1997 | ||
| S | 1999 | ||
| T | 2003 | ||
| U | 2006 | ||
| V | 2007 | ||
| X | 2009 | ||
| Y | 2009 | ||
| Z | 2010 | ||
| IBC | ES6 | ||
| NEPHROLOGY | ES6 | ||
| NEUROLOGY | ES6 | ||
| OPHTHALMOLOGY | ES6 | ||
| ORTHOPEDICS | ES6 | ||
| OTORHINOLARYNGOLOGY (ENT) | ES7 | ||
| PEDIATRICS | ES7 | ||
| PSYCHIATRY | ES7 | ||
| PULMONARY DISEASE | ES7 | ||
| RHEUMATOLOGY | ES8 | ||
| SURGERY, GENERAL | ES8 | ||
| UROLOGY | ES8 | ||
| INTERDISCIPLINARY MEDICINE | ES8 |